Fulcrum Therapeutics (FULC) risk factors
Item 1A of every Fulcrum Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors83 risks2 new2 dropped14 reworded
Federal net operating loss carryforwards grew to $102.8 million as of December 31, 2025. Orphan drug designation risks were updated to address pociredir for sickle cell disease. Collaboration partnership disclosures shifted to focus on partner competition.
Filed Feb 24, 2026 - FY2024 10-K risk factors83 risks
Fulcrum Therapeutics faces significant ongoing operating losses, with an accumulated deficit of $519.4 million as of December 31, 2024. The company suspended development of losmapimod after its Phase 3 REACH trial failed its primary endpoint. Current development relies heavily on pociredir and maintaining sufficient cash to fund operations into 2027.
Filed Feb 25, 2025